JAK inhibitors in rheumatology
Introduction Janus kinase inhibitors (JAKis) are a class of drugs that differ from biologics in their mechanism of action and are rapidly gaining traction in the field of rheumatology. JAK,…
1 Comment
August 4, 2023
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Introduction Rheumatoid arthritis (RA) is an autoimmune disease that affects multiple joints symmetrically and can also affect other organs. It has a prevalence of around 1% globally and affects women…
June 16, 2023
Personalized Medicine in Rheumatoid Arthritis: Combining Biomarkers and Patient Preferences To Guide Therapeutic Decisions
Introduction The last few decades have seen major therapeutic advancements in rheumatoid arthritis (RA) therapeutics. New disease-modifying antirheumatic drugs (DMARDs) have created more choices for people, but no therapeutic works…
May 5, 2023
Association Between Novel Hematological Indices and Measures of Disease Activity in Patients with Rheumatoid Arthritis
Introduction Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation, bone erosion, and cartilage destruction that leads to joint damage and deformity. Recent advances in pathogenesis…
April 28, 2023
Altered lipid metabolism in synovial fibroblasts of individuals at risk of developing rheumatoid arthritis
Abstract Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mostly affects the synovial joints. It is characterised by chronic inflammation that causes painful swelling and may ultimately lead to…
March 2, 2023
Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
Introduction Rheumatoid arthritis (RA) is a chronic condition characterised by periods of remission alternated with disease reactivations (ie, flares). Though RA treatment options are rapidly growing, glucocorticoids are still frequently…
February 23, 2023
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials
Abstract In the treatment of rheumatoid arthritis (RA), Janus kinase inhibitors (jakinibs) represent an emerging class of targeted therapies in addition to biologics. The number of jakinibs has been growing…
December 23, 2022
From vaccines to nanovaccines: A promising strategy to revolutionize rheumatoid arthritis treatment
Abstract Rheumatoid arthritis (RA) is a joint-related autoimmune disease that is difficult to cure. Most therapeutics act to alleviate the symptoms but not correct the causes of RA. Novel strategies…
December 21, 2022
Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations
Introduction Treatments used for rheumatoid arthritis (RA) are under investigation for their efficacy to prevent RA in at risk groups. It is therefore important to understand treatment preferences of those…
November 8, 2022
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Introduction In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; n = 164), patients with low/absent synovial B cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal…
October 7, 2022
